USPTO serial 79412141
INDERO CRO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 19, 2026
- Examiner
- DRUHAN, CONNOR M
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INDERO CRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles G. Zug
Charles G. Zug Nelson Mullins Riley & Scarborough LLP301 S. College St.Suite 2300, IP DepartmentCharlotte, NC 28202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Distributorship services for others in the fields of cameras and imaging equipment for use in the field of dermatology and laboratory equipment for use in the field of clinical research; electronic data collection services for business purposes in the field of preclinical and nonclinical research, clinical trials and technical studies related to pharmaceutical and biological drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; collection and compilation of information into computer databases in the field of preclinical and nonclinical research, clinical trials and technical studies related to pharmaceutical and biological drugs for human and veterinary use | ACTIVE | — |
| 042 | Medical and scientific research, namely, conducting clinical trials for others; Providing medical and scientific research information on the design and management of clinical trials; Scientific research in relation to the design and management of clinical trials and development of clinical trials in the fields of pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; Medical and scientific research, namely, designing, developing protocols for, organizing, conducting, monitoring, and managing clinical trials and preclinical and nonclinical research studies, research support services and research project management services in relation to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products for others; Consulting services for others in the field of medical and scientific research, namely, clinical trials and preclinical and nonclinical research studies, research support services and research project management services in relation to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; Calibration services, namely, the calibration of electronic data for the purpose of conducting clinical trials and preclinical and nonclinical research studies related to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; Electronic storage of data in the field of clinical trials and preclinical and nonclinical research studies related to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; Medical research services, namely, research assistance services and research project management services for the purpose of designing and conducting clinical trials in relation to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products; Scientific research in relation to the designing and conducting of clinical trials in the fields of data management and biostatistics; Providing scientific information on the design and management of clinical trials and preclinical and nonclinical research studies; Research assistance services and research project management services for the purpose of designing and conducting clinical trials in relation to pharmaceutical and biologic drugs for human and veterinary use, natural health products, and medical devices | ACTIVE | — |
| 044 | Medical testing services in relation to subjects in clinical trials of pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices and other therapeutic products | ACTIVE | — |
| 045 | Regulatory compliance consulting and advisory services in relation to pharmaceutical and biologic drugs for human and veterinary use, natural health products, medical devices | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Indero Inc.
- Other trademarks owned by Indero Inc.
- Other trademarks owned by Indero Inc.
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named INDERO CRO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 19, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 28, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| May 19, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 19, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 19, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Mar 31, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 31, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 6, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2026 | UNTD | REQUEST TO DIVIDE UNTIMELY, REFUSED, OR WITHDRAWN | — |
| Feb 26, 2026 | IROA | RESPONSE TO ITU OFFICE ACTION ENTERED | — |
| Feb 26, 2026 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 25, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 20, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 20, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 20, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 20, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 10, 2026 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Sep 9, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 9, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 9, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 15, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 15, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 15, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 8, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 18, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 18, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 7, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 6, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 13, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 13, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |